GlassScriptPhysician profile
Timothy Alan Corba
NPI 1356458202
$3,698.94
in general payments reported to CMS, 2019-2025
26 companies · $407 in 2025
The $407 reported for 2025 was more than what 91% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $510 · 2020: $524 · 2021: $655 · 2022: $571 · 2023: $371 · 2024: $661 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,439.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,439.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $744.94 | 2021-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $462.99 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $444.71 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $339.88 | 2021-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $320.18 | 2019-2022 | |
| Adlon Therapeutics L.P. | $190.09 | 2019-2021 | |
| Neos Therapeutics, LP | $189.80 | 2019-2023 | Cotempla Xr-Odt |
| Glaxosmithkline, LLC. | $156.35 | 2019-2024 | Bexsero, Rotarix, Pediarix |
| Collegium Pharmaceutical, INC. | $143.47 | 2025 | Jornay Pm |
| Pfizer INC. | $142.76 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $140.46 | 2021-2025 | Gardasil 9, Vaxelis, M-M-R II |
| Shire North American Group INC | $69.56 | 2019 | |
| Seqirus USA INC | $53.80 | 2021-2025 | Flucelvax |
| Sanofi Pasteur INC. | $47.99 | 2019-2022 | |
| Cranial Technologies, INC | $42.87 | 2024-2025 | Doc Band |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $23.58 | 2021 | |
| Verrica Pharmaceuticals INC. | $23.41 | 2024 | Ycanth |
| Neurelis, INC. | $22.83 | 2023 | Valtoco |
| Mckesson Medical-Surgical, INC. | $22.05 | 2023 | |
| Lnhc, INC | $19.39 | 2025 | Zelsuvmi |
| Abbott Laboratories | $18.44 | 2024 | Id Now Instrument |
| Sanofi-Aventis U.S. LLC | $18.03 | 2025 | |
| Arbor Pharmaceuticals, INC. | $17.02 | 2019 | |
| Sobi, INC | $16.59 | 2020 | |
| Sarepta Therapeutics, INC. | $16.35 | 2019 | |
| Kaleo, INC. | $11.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Corba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.